The FDA recently expanded the indication for enzalutamide for the treatment of all men with metastatic and nonmetastatic castration-resistant prostate cancer on the basis of the PROSPER trial. Now that both disease states can have the same treatment, the need to thoroughly identify metastatic lesions is questioned.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465–2474 (2018).
Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408–1418 (2018).
Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
Beer, T. M. & Tombal, B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 1755–1756 (2014).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Chandler, R. & de Bono, J. Second-generation antiandrogens in nonmetastatic CRPC. Nat. Rev. Urol. 15, 342–344 (2018).
Gomella, L. G. Prostate cancer CRPC stage M0 and M1: do we need stage M0.5? Can. J. Urol. 25, 9220 (2018).
Li, R. et al. The use of PET/CT in prostate cancer. Prostate Cancer Prostat. Dis. 21, 4–21 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT02319837 (2018).
Whitney, C. et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. (in the press).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.F. is a consultant to Pfizer, Astellas, and Janssen. H.Z. declares no competing interests.
Rights and permissions
About this article
Cite this article
Zhao, H., Freedland, S. Enzalutamide treatment for the whole spectrum of CRPC. Nat Rev Urol 15, 663–665 (2018). https://doi.org/10.1038/s41585-018-0090-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0090-1